FDA Permits Last-Resort Iclusig Use After Clinical Trial Deaths

By Jeff Overley (December 20, 2013, 7:04 PM EST) -- Two months after announcing a spate of deaths, the U.S. Food and Drug Administration on Friday allowed Ariad Pharmaceuticals Inc. to resume sales of leukemia drug Iclusig to a narrower universe of patients who will receive stronger warnings about the product's serious risks.

The return comes after at least 14 people died while taking Iclusig in clinical trials that were intended to get a fuller picture of the drug's safety and effectiveness after it received fast-track approval last year to treat two rare types of leukemia. The drug will still be available for the same conditions, but instead of being used as...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Related Sections

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!